(3.238.190.82)
Users online: 1429    [ij] [ij] [ij] 
Email id
 

Asian Journal of Pharmacy and Technology
Year : 2016, Volume : 6, Issue : 4
First page : ( 207) Last page : ( 216)
Print ISSN : 2231-5705. Online ISSN : 2231-5713.
Article DOI : 10.5958/2231-5713.2016.00031.3

Formulation, Evaluation and comparative study of Zolmitriptan Mouth Dissolving Tablet

Aher V. S., Bhairav B. A.*, Saudagar R. B.

Department of Quality Assurance Techniques, R. G. Sapkal College of Pharmacy, Anjaneri, Nashik, Maharashtra, India

*Corresponding Author E-mail: vaishaliaher91@gmail.com

Online published on 30 December, 2016.

Abstract

Migraine is likely due to local cranial vasodilation and to release of sensory neuropeptide through nerve ending in the trigeminal system. Zolmitriptan is Serotonin 5-HT1D receptor agonist. It gives relief from pain, headache, and other symptoms of migraine including nausea, vomiting and sensitivity to light/sound. In this study, mouth dissolving tablets were prepared by direct compression method. In the present work efforts have been made to formulation, evaluation and comparative study of Zolmitriptan mouth dissolving tablet by using direct compression method. Release profile of F-7 having 40% Croscarmellose sodium (disintegrant) and 13.3% Microcrystalline cellulose (suspending agent) in direct compression method was found to have maximum release of 99.24%. The drug release from all batches was found to be concentration dependent. Hence, the formulation of F-7 fulfills the objective of the present study.

Top

Keywords

Zolmitriptan, direct compression, mouth dissolving tablet, croscarmellose sodium, microcrystalline cellulose.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
458,376,737 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.